Dopamine agonist withdrawal syndrome — what do we really know?
Further research should focus on the natural evolution, risk factors, and duration of DAWS. Development of new generation DAs, such as tavapadon, which may reduce the side effects of dopaminergic therapy, may set new standards for treatment. Guidelines on the taper velocity of DAs, risk factors, and management therapies are to be established to improve detection and treatment of DAWS.
Authors
- Jarosław Sławek (ORCID: https://orcid.org/0000-0001-6816-0877)
- Iga Alicja Łobińska
Institutions
- Copernicus Memorial Hospital (PL)
- Gdańsk Medical University (PL)
Publication Details
- Journal
- Neurologia i Neurochirurgia Polska
- Published
- 2026-03-23
- DOI
- https://doi.org/10.5603/pjnns.110733
- Primary Topic
- Alcoholism and Thiamine Deficiency
- Type
- article
- Field-Weighted Citation Impact
- 0.00